血小板聚集率在心血管疾病及抗血小板治疗中的作用与意义

Platelet aggregation in cardiovascular diseases and antiplatelet therapy

血小板聚集率是反映血小板生理功能或病理学损害的一个重要指标。在临床上观察到,诸多心血管疾病可出现血小板反应性增强,使其聚集率增加,从而促发血栓形成,引发心血管事件。临床上常用的抗血小板药物阿司匹林和氯吡格雷能有效降低心血管事件风险。但部分患者对这些药物存在"抵抗",他们在治疗期间仍可能发生血栓事件。如何评价心血管疾病患者及其治疗期间的血小板反应性以指导个体化治疗是临床医师关注的热点,本文就此方面的研究进展进行简要综述。

Platelet aggregation is an important indicator which reflects physiological function and pathologi- cal damage of the platelet. The high platelet activation and increased aggregation can be seen in patients with cardiovascular diseases, which may induce thrombosis and lead to cardiovascular events. Aspirin and clopido- grel, the commonly used antiplatelet drugs, can significantly reduce the risk of cardiovascular events. However, because of ＂aspirin and/or clopidogrel resistance＂ thrombotic events still occur in some patients receiving an- tiplatelet therapy. It has become a hot topic how to evaluate cardiovascular patients and on-treatment platelet reactivity to guide individualized treatment. This review presents the latest reaserch progress in the field.